Investor
Propel Bio Management, LLC
CIK 0001969764 · filed 2026-05-14 · SEC filing
13F book
$158.7M
Positions
38
22 new · 4 sold
Largest name
19.0%
Plains Gp Hldgs L P
Est. mark
−$11.4M
Price effect on 16 names still held. Flow $53M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Plains Gp Hldgs L P | — | 1.27M | $30.2M | 19.0% | $5.83M | Held |
| Achieve Life Sciences, Inc. | ACHV | 3.79M | $11.4M | 7.2% | −$7.45M | Held |
| Phathom Pharmaceuticals, Inc. | PHAT | 841.3K | $9.35M | 5.9% | −$4.05M | Added−$2.94M |
| Delcath Sys Inc | — | 979.7K | $9.16M | 5.8% | −$329.2K | Added$4.73M |
| Corcept Therapeutics Inc | CORT | 147.8K | $6.02M | 3.8% | — | New |
| Abeona Therapeutics Inc. | ABEO | 1.33M | $6.01M | 3.8% | −$625.1K | Added$1.63M |
| Vor Biopharma Inc. | VOR | 314.5K | $5.59M | 3.5% | — | New |
| Kyverna Therapeutics, Inc. | KYTX | 644.4K | $5.59M | 3.5% | −$472K | Cut−$681.1K |
| Milestone Pharmaceuticals In | — | 4.12M | $5.08M | 3.2% | −$3.24M | Held |
| Celldex Therapeutics Inc New | — | 131.4K | $4.14M | 2.6% | $567.3K | Cut−$55.7K |
| Compass Pathways Plc | CMPS | 742K | $4.12M | 2.6% | −$1M | Cut−$1.83M |
| Viridian Therapeutics Inc | — | 210.2K | $4.09M | 2.6% | −$2.45M | Cut−$4.7M |
| Inventiva Sa | — | 724.7K | $3.99M | 2.5% | $624.9K | Cut−$655.4K |
| Sab Biotherapeutics Inc | — | 1.01M | $3.89M | 2.5% | $63.6K | Added$1.44M |
| Orchestra Biomed Hldgs Inc | — | 896.7K | $3.83M | 2.4% | — | New |
| 4d Molecular Therapeutics In | — | 380.4K | $3.58M | 2.3% | — | New |
| Oculis Holding Ag | — | 122.2K | $3.28M | 2.1% | $838.4K | Cut−$172.4K |
| Ocular Therapeutix, Inc | OCUL | 382.4K | $3.23M | 2.0% | — | New |
| Upstream Bio, Inc. | UPB | 341.8K | $3.1M | 2.0% | — | New |
| Aquestive Therapeutics, Inc. | AQST | 711K | $2.95M | 1.9% | — | New |
| EyePoint, Inc. | EYPT | 215.8K | $2.79M | 1.8% | — | New |
| Trevi Therapeutics, Inc. | TRVI | 223.8K | $2.65M | 1.7% | — | New |
| Zevra Therapeutics, Inc. | ZVRA | 282.4K | $2.64M | 1.7% | $24.9K | Added$2.07M |
| Immunic, Inc. | IMUX | 2.34M | $2.62M | 1.7% | — | New |
| Coherus Oncology, Inc. | CHRS | 1.42M | $2.41M | 1.5% | — | New |
| Ovid Therapeutics Inc. | OVID | 921.5K | $2.04M | 1.3% | — | New |
| Palisade Bio, Inc. | PALI | 1.11M | $2M | 1.3% | — | New |
| Kalaris Therapeutics, Inc. | KLRS | 295.8K | $1.72M | 1.1% | −$110.2K | Added$1.37M |
| Uniqure Nv | — | 104.8K | $1.71M | 1.1% | — | New |
| Athira Pharma Inc | LONA | 149.3K | $1.5M | 0.9% | $365.7K | Held |
| Nuvation Bio Inc. | NUVB | 329.3K | $1.41M | 0.9% | — | New |
| Maze Therapeutics, Inc. | MAZE | 43.8K | $1.31M | 0.8% | — | New |
| Evommune, Inc. | EVMN | 55.7K | $1.28M | 0.8% | — | New |
| Corvus Pharmaceuticals, Inc. | CRVS | 85.8K | $1.25M | 0.8% | — | New |
| Aldeyra Therapeutics, Inc. | ALDX | 730.6K | $1.23M | 0.8% | — | New |
| Artiva Biotherapeutics, Inc. | ARTV | 146.4K | $949.8K | 0.6% | — | New |
| Connect Biopharma Hldgs Ltd | — | 209.5K | $553.9K | 0.3% | — | New |
| Satellos Bioscience Inc. | MSLE | 10.1K | $57.1K | 0.0% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.